Lenalidomide Eg (Lenalidomide)

The drug binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, changing its substrate profile. This leads to degradation of specific transcription factors, producing anti‑angiogenic effects, enhancing immune cell activity, and directly inhibiting the growth of malignant plasma cells.

The prescribed dose is individualized by the treating physician based on the specific indication, the patient’s renal function, prior therapies, and overall clinical status. No fixed dosing regimen can be provided without a medical assessment.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. It is also not recommended for breastfeeding mothers because it may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements), and necessary import documentation.

Lenalidomide shares the same class as thalidomide but has a more favorable safety profile, especially regarding peripheral neuropathy. It also exhibits stronger anti‑angiogenic and immunomodulatory activity, allowing lower dosing and improved efficacy in the approved hematologic malignancies.

Store the tablets at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original blister pack, protect from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Lenalidomide Eg is taken orally as a tablet, usually with water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

The most critical safety concerns include the risk of deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infection, and the potential development of secondary primary malignancies. Patients should be monitored closely for signs of clotting, infection, and any new cancer diagnoses.

Lenalidomide is contraindicated in pregnant women, individuals who cannot use effective contraception, patients with known hypersensitivity to the drug, and those with uncontrolled severe infections. Caution is also advised for patients with significant renal impairment or a history of thromboembolic events.